cerdulatinib topical (DMVT-502) / Roivant - LARVOL DELTA

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies. (PubMed, J Cutan Med Surg) - "FDA-approved oral therapies include bexarotene and vorinostat, both of which are effective in patients who are recalcitrant to prior topical therapies. Off-label oral therapies include methotrexate, acitretin, and chlorambucil...Chlorambucil is mainly used to treat erythrodermic MF. Investigational oral therapies for MF include tenalisib, duvelisib, cerdulatinib, lenalidomide, bortezomib, and azacytidine, and direct comparison studies between these investigational agents and FDA-approved therapies should be undertaken to better understand their role in the management of MF and SS."

Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

The future of topical JAK inhibitors in the treatment of atopic dermatitis. (PubMed, Expert Opin Pharmacother) - "In this review, we summarize research about topical JAKinibs, including ruxolitinib, tofacitinib, delgocitinib, cerdulatinib, and bredocitinib, which target multiple cytokine pathways and have been shown to reduce the itch and inflammation...The main limitation of predominantly short-term studies is that the long-term effects of JAK inhibitor therapy are not yet fully known. The body of research is growing and more information about their effectiveness and safety is being added each year."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Efficacy and Safety of Topical JAK inhibitors in the Treatment of Atopic Dermatitis in Pediatrics and Adults: A Systematic Review. (PubMed, Exp Dermatol) - "Available topical JAKi are effective and safe modalities in treating AD. Nevertheless, further studies with longer duration and head-to-head comparative trials are necessary to find the best option with the least adverse effects."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics • Pruritus

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis. (PubMed, J Invest Dermatol) - No abstract available

Clinical • Journal • P1 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo (clinicaltrials.gov) - P2a; N=33; Completed; Sponsor: Dermavant Sciences GmbH; Recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Nov 2020; Trial primary completion date: Jul 2020 ➔ Nov 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Dermatology • Vitiligo

Introduced tapinaroff drug for JT skin disease, joint development with Torii from Dermavant of Switzerland [Google Translation] (Mix Online) - "Under the agreement with Dermavant, JT has an exclusive development and commercialization of Tapinarov's backup compounds and compounds currently being developed by Dermavant (DMVT-502, DMVT-503, DMVT-504) for skin diseases in Japan."

Licensing / partnership

Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo (GlobeNewswire, Dermavant Sciences, Inc.) - "Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligo. Top-line results anticipated in second half of 2020....Dermavant Sciences...today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib."

Enrollment status • P2a data • Trial status

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo (clinicaltrials.gov) - P2a; N=30; Recruiting; Sponsor: Dermavant Sciences GmbH

Clinical • New P2a trial